Sarfaraz K. Niazi (@moustaches) header
Sarfaraz K. Niazi (@moustaches) profile picture

Sarfaraz K. Niazi

@moustaches

Teacher, inventor, author, drug innovator, and an optimist

 Chicago, Illinois
niazi.com
Joined April 2009
  • Tweets393
  • Following142
  • Followers727
39Media
Photo by Sarfaraz K. Niazi (@moustaches)Photo by Sarfaraz K. Niazi (@moustaches)Photo by Sarfaraz K. Niazi (@moustaches)Photo by Sarfaraz K. Niazi (@moustaches)Photo by Sarfaraz K. Niazi (@moustaches)Photo by Sarfaraz K. Niazi (@moustaches)Photo by Sarfaraz K. Niazi (@moustaches)Photo by Sarfaraz K. Niazi (@moustaches)Photo by Sarfaraz K. Niazi (@moustaches)
url310.tandfonline.com/ls/cl…
2
Glad to announce the FDA accepting my petition prnewswire.com/news-releases…
FDA Issues Landmark Biosimilar Guidance Incorporating Regulatory Reforms Advised by Professor...

FDA Issues Landmark Biosimilar Guidance Incorporating Regulatory Reforms Advised by Professor...

/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4)1,...

prnewswire.com
1
53
My paper, published yesterday, addresses a very difficult topic: how to understand empathy. Is it different between men and women? Read it. frontiersin.org/journals/psy…
Frontiers | Therapeutic modulation of empathy: pharmacological, neurostimulation, and behavioral...

Frontiers | Therapeutic modulation of empathy: pharmacological, neurostimulation, and behavioral...

Empathy is a core neurobiological capacity that enables humans to perceive, understand, and respond to others’ experiences, yet its deliberate modulation as ...

frontiersin.org
48
This is to inform you all that I am not participating in this event. If you need any advice, write to me at [email protected]. It is all free. You can also read my paper that tells the whole story: mdpi.com/1424-8247/18/8/1157
Image from Sarfaraz K. Niazi (@moustaches)
1
47
#NewProfilePic
Image from Sarfaraz K. Niazi (@moustaches)
1
36
Slowly, my views are gaining acceptance of how to be rational in developing biosimilars: managedhealthcareexecutive.c…
The FDA proposes ditching comparative efficacy studies for biosimilars | Managed Healthcare...

The FDA proposes ditching comparative efficacy studies for biosimilars | Managed Healthcare...

To gain approvals, biosimilar manufacturers could do faster, less expensive analytical studies of their products' composition.

managedhealthcareexecutive.com
40
📢#Specialissue: #Biosimilars #Development Strategies ⏰Deadline: 25 November 2025 🎓Guest Editors: Dr. Sarfaraz K. Niazi and Dr. Sesselja S. Ómarsdóttir 📖Find out more at mdpi.com/journal/pharmaceuti… @MDPIBiologySubj
Image from Pharmaceuticals MDPI (@Pharmaceut_MDPI)
1
3
4
107
linkedin.com/posts/skniazi_b…

Biosimilar Council fails to support biosimilars | Sarfaraz K. Niazi

I have filed a report with the US Senate. At the Ways and Means Subcommittee meeting, the four witnesses who were invited failed to push for the only change in the legislature to eliminate clinical...

linkedin.com
45
Businesses across country remain closed in solidarity with Palestinians dawn.com/news/1906709
Businesses across country remain closed in solidarity with Palestinians

Businesses across country remain closed in solidarity with Palestinians

Nationwide strike observed on JI's call to protest against Israeli atrocities in Gaza; party stages rallies in various cities.

dawn.com
1
63
So who is losing. What idiotic move.
45
linkedin.com/posts/skniazi_p…
Professor Niazi Challenges the 2024 Chemistry Nobel Prize that the 3D Protein Structure cannot be...

Professor Niazi Challenges the 2024 Chemistry Nobel Prize that the 3D Protein Structure cannot be...

My paper published today challenging the Nobel Committee as well as the algorithms AlphaFold and Rosetta; you cannot ever predict the 3D structure at the site of action, I have proven and provided...

linkedin.com
1
59
linkedin.com/posts/skniazi_b…

BioRationality: FDA Needs More Time Before Working With USP on Biosimilars Development | Sarfaraz...

The FDA has responded to my petition asking for more time to decide; if the FDA accepts it, the USP can be invited to develop a release specification, removing the need for securing a reference...

linkedin.com
1
56
linkedin.com/posts/skniazi_b…
BioRationality: A Socratic Analysis of IQVIA Report on Biosimilars | Sarfaraz K. Niazi

BioRationality: A Socratic Analysis of IQVIA Report on Biosimilars | Sarfaraz K. Niazi

My article today criticizes IQVIA for appearing to support biosimilars, but their income comes from clinical trials; there is no mention of removing these in the report, but the Biosimilars Council...

linkedin.com
2
39
Full article: Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs tandfonline.com/doi/full/10.…
Contradicting rulings of the US patent office on double patenting jeopardize the generic and...

Contradicting rulings of the US patent office on double patenting jeopardize the generic and...

Obviousness-type double patenting is allowed only in the US, but only if a terminal disclaimer and the same ownership are made for the expiry of the patent. Historically, this provision has hampere...

tandfonline.com
2
46
linkedin.com/posts/skniazi_b…

BioRationality: No More Biosimilars—Just Biogenerics | Sarfaraz K. Niazi

My views: No more Biosimilars. End of an era of confusion

linkedin.com
1
34
linkedin.com/posts/skniazi_t…

The Top 5 Biosimilar Articles for the Week of January 27 | Sarfaraz K. Niazi

Read my thoughts that keep me in the top of the list about biosimilars. https://lnkd.in/gs4DucS4

linkedin.com
1
39
linkedin.com/posts/skniazi_b…

BioRationality: Biosimilar Associations and Stakeholders Representing Biosimilars | Sarfaraz K....

My criticism of Biosimilar Associations wasting millions of dollars doing what’s unnecessary and missing out what’s needed because they are politicians not scientists

linkedin.com
29
linkedin.com/posts/skniazi_b…

BioRationality: Biosimilar Associations and Stakeholders Representing Biosimilars | Sarfaraz K....

My criticism of Biosimilar Associations wasting millions of dollars doing what’s unnecessary and missing out what’s needed because they are politicians not scientists

linkedin.com
21
centerforbiosimilars.com/vie…
The Top 5 Most-Read Policy Articles of 2024

The Top 5 Most-Read Policy Articles of 2024

The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction...

centerforbiosimilars.com
1
33
linkedin.com/posts/skniazi_t…
The Top 5 Most-Read Policy Articles of 2024 | Sarfaraz K. Niazi

The Top 5 Most-Read Policy Articles of 2024 | Sarfaraz K. Niazi

I made to the top and also to number 2 of the top 5 most read policy articles on biosimilars in 2024. Thanking my readers https://lnkd.in/gCExHiy6

linkedin.com
2
29
linkedin.com/posts/skniazi_b…

BioRationality: Withdrawal of Proposed Terminal Disclaimer Rule Spells Major Setback for Biosimil...

We lost great opportunity. My article today suggests a challenge for Biosimilars Council to sue the US Patent Office if not then I will do it to remove double patenting. Inviting lawyers to help me...

linkedin.com
1
37
Load more